Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Phys Written Answerspharmacological

Phys Written Answers · pharmacological

Serotonin Syndrome and NMS — Written Clinical Reasoning

DCE long-case preparation: structured written reasoning for the recognition and management of serotonin syndrome and neuroleptic malignant syndrome, including the Hunter criteria, the SS-versus-NMS distinction, cyproheptadine and dantrolene pharmacology, and the management of withdrawal-emergent NMS in Parkinson disease.

5 min readSource-verified ·

Target exams

FRACP DCEMRCP Part 2
On this page
Study tools

Target exams

FRACP DCEMRCP Part 2
Prompt
DCE long-case preparation: structured written reasoning for the recognition and management of serotonin syndrome and neuroleptic malignant syndrome, including the Hunter criteria, the SS-versus-NMS distinction, cyproheptadine and dantrolene pharmacology, and the management of withdrawal-emergent NMS in Parkinson disease.

SAQ 1 — Recognition and Management of Serotonin Syndrome (20 marks, 30 minutes)

Prompt: Outline your integrated management of this patient, including: (a) the diagnosis and the clinical reasoning that supports it; (b) the immediate pharmacological and supportive management with exact drugs, doses and rationale; (c) how you would distinguish this from neuroleptic malignant syndrome and anticholinergic toxicity; (d) the complications you must monitor for in the first 48 hours; and (e) the plan for her psychiatric medication once she recovers. [1]

Model Answer

(a) Diagnosis and clinical reasoning (4 marks): [1]

The diagnosis is serotonin syndrome, precipitated by the combination of three serotonergic agents — sertraline (an SSRI blocking serotonin reuptake), tramadol (also a serotonin reuptake inhibitor), and linezolid (a weak reversible monoamine oxidase inhibitor blocking serotonin metabolism) [1][5]. The addition of linezolid to her existing sertraline and tramadol created a multiplicative rise in synaptic serotonin. She fulfils the Hunter Serotonin Toxicity Criteria — recent serotonergic drug exposure plus inducible clonus with agitation and diaphoresis [2]. The clinical triad is present: neuromuscular hyperactivity (inducible and ocular clonus, lower-limb hyperreflexia, tremor), autonomic instability (hyperthermia, tachycardia, hypertension, mydriasis, diaphoresis), and altered mental status (agitation, confusion) [1]. The rapid onset within 18 hours of the drug interaction is characteristic; NMS evolves over days to weeks, not hours [4].

(b) Immediate management (6 marks): [1]

  1. Stop all serotonergic agents immediately — cease sertraline, tramadol, and linezolid. Substitute linezolid with a non-serotonergic alternative for her MRSA osteomyelitis (vancomycin). Review all medications, over-the-counter agents (especially cough suppressants containing dextromethorphan), and herbal agents (St John's wort). [1]

  2. Airway, breathing, circulation — high-flow oxygen; establish intravenous access; continuous cardiac monitoring for arrhythmia. Her airway is currently protected but she must be monitored closely for deterioration. [1]

  3. Benzodiazepines as first-line — diazepam 5 to 10 mg intravenously, repeated every 5 to 10 minutes as required, titrated to control agitation and reduce muscle tone. Benzodiazepines enhance GABAergic inhibition, which indirectly reduces serotonergic tone, and by controlling agitation and rigidity they reduce the muscle-generated heat driving her hyperthermia [1]. Lorazepam 1 to 2 mg intravenously is an alternative.

  4. Active cooling — remove clothing, evaporative cooling, fans, ice packs to groins and axillae. Antipyretics (paracetamol) will not work because the hyperthermia is muscle-generated, not prostaglandin-mediated. [1]

  5. Intravenous fluids — isotonic crystalloid to maintain urine output and protect against rhabdomyolysis-induced acute kidney injury. Target urine output 1 to 2 mL/kg/hour. [1]

  6. Cyproheptadine for moderate-to-severe disease — a 5-HT2A receptor antagonist. Initial dose 12 mg orally (via nasogastric tube if needed), then 2 mg every 2 hours until clinical response (maximum 32 mg in 24 hours), then maintenance 8 mg every 6 hours. Limitation: oral only, no intravenous formulation, evidence limited to case series [5].

  7. Escalation if severe — if she develops temperature above 41 degrees, rigidity, seizures, or loss of airway reflexes, intubate and paralyse with a non-depolarising neuromuscular blocker (rocuronium 1.0 to 1.2 mg/kg for intubation). Avoid succinylcholine because of the risk of hyperkalaemia from rhabdomyolysis and theoretical malignant hyperthermia unmasking [1].

(c) Distinguishing from NMS and anticholinergic toxicity (4 marks): [1]

From NMS: NMS is caused by dopamine D2 blockade (antipsychotics) or dopamine withdrawal, with a gradual onset over days to weeks, lead-pipe rigidity (greater in the upper limbs), bradyreflexia (not hyperreflexia or clonus), and a markedly elevated creatine kinase (often into the thousands) [3]. This patient has hours of onset, clonus and hyperreflexia, a mild CK (480), and a clear serotonergic drug trigger — all pointing away from NMS [4].

From anticholinergic toxicity: anticholinergic toxicity produces dry skin and dry mucous membranes (anhidrosis), urinary retention, and decreased bowel sounds (ileus). This patient is diaphoretic with active bowel sounds and diarrhoea — the opposite pattern. Clonus is not a feature of anticholinergic toxicity. The mnemonic for anticholinergic toxicity ('dry as a bone, red as a beet, blind as a bat, mad as a hatter') contrasts with the wet, hyperkinetic picture of serotonin syndrome [5].

(d) Complications to monitor in the first 48 hours (3 marks): [1]

  • Rhabdomyolysis and acute kidney injury — serial creatine kinase, creatinine, urine output. Treat with aggressive intravenous fluids; consider sodium bicarbonate if severe acidosis or myoglobinuria.
  • DIC and coagulopathy — serial INR, APTT, fibrinogen, D-dimer, platelets.
  • Arrhythmia — continuous cardiac monitoring; correct potassium, calcium, magnesium.
  • Seizures — benzodiazepines; watch for non-convulsive status if mental status fails to improve.
  • Aspiration — from reduced consciousness and agitation; consider early airway protection.
  • Hepatic dysfunction — serial liver function tests. [1]

(e) Psychiatric medication plan after recovery (3 marks): [1]

The underlying depression must not be neglected. After full resolution of serotonin syndrome (typically 24 to 72 hours), serotonergic antidepressants can usually be re-introduced cautiously — a single agent at low dose, with careful monitoring, avoiding combinations and MAOIs [1]. The risk of recurrence with a single SSRI at standard dose is low. I would involve the consultation-liaison psychiatry team early to plan the re-challenge. Tramadol should be replaced with a non-serotonergic analgesic (e.g., oxycodone, paracetamol-based regimens). I would document the linezolid-serotonergic interaction as a drug allergy/adverse reaction in her medication record and warn her and her family about combining serotonergic agents in the future.


Physician Medicine Pro

Continue reading

You have read the opening of this written answer. The complete unit — every section and its primary-source references — is part of the Physician Medicine fellowship library.

Sign in to continueSee pricing
References6ShowHide
  1. [1]Boyer EW, Shannon M The serotonin syndrome N Engl J Med, 2005.PMID 15784664
  2. [2]Dunkley EJC, Isbister GK, Sibbritt D, Dawson AH, Whyte IM The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity QJM, 2003.PMID 12925718
  3. [3]Berman BD Neuroleptic malignant syndrome: a review for neurohospitalists Neurohospitalist, 2011.PMID 23983836
  4. [4]Perry PJ, Wilborn CA Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management Ann Clin Psychiatry, 2012.PMID 22563571
  5. [5]Volpi-Abadie J, Kaye AM, Kaye AD Serotonin syndrome Ochsner J, 2013.PMID 24358002
  6. [6]Trollor JN, Chen X, Sachdev PS Neuroleptic malignant syndrome associated with atypical antipsychotic drugs CNS Drugs, 2009.PMID 19480467
Physician Medicine Pro

$29/ monthor $279 / year

The complete Physician Medicine library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousSalicylate Toxicity — Written Clinical ReasoningpharmacologicalNextTherapeutic Drug Monitoring — Written Clinical Reasoningpharmacological